Resultados de la búsqueda 831-840 of 15043 for Guillain-Barre Syndrome

1. Ensayos clínicos - Neurología

   FTLD is a neurodegenerative disorder of the nervous system which there are no approved treatments or cures. The study has two arms: a “longitudinal arm ...

2. Ensayos clínicos - Neurología

   The purposes of this study are to compare the functional connectivity in adolescent patients with Postural Orthostatic Tachycardia Syndrome (POTS) both with ...

3. Lesión de la médula espinal - Médicos y departamentos - Mayo Clinic

   ... Guillain Barré, Parálisis cerebral, Espasticidad, Trastorno del movimiento, Tortícolis, trastorno neuroevolutivo, Distonía, Síndrome de Angelman, neuropatía ...

4. Neurología - Ensayos clínicos

   There is evidence that neurodegenerative changes precede clinical symptoms in Alzheimer's disease by two decades (Villemagne et al, 2013). Early detection is ...

5. New immunotherapy approved for metastatic bladder cancer

   Share · Tweet. July 29, 2021 . VID-20309782. Inicio; New immunotherapy approved for metastatic bladder cancer. Tu donación es muy poderosa.

6. Ensayos clínicos - Medicina cardiovascular

   Rochester, Minn. Spontaneous coronary artery dissection (SCAD) is uncommon but important cause of acute coronary syndrome and sudden cardiac death. There is ...

7. Enfermedad de Behcet - Diagnóstico y tratamiento - Mayo Clinic

   Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug. 7, 2024. AskMayoExpert. Behcet syndrome. Mayo Clinic, 2023. Smith EL, et al. Clinical manifestations ...

8. Ensayos clínicos - Neurología

   Jacksonville, Fla. The primary purpose of this study is to create a Mayo Clinic repository for neurodegenerative disorders such as Parkinson's disease (PD), ...

9. Síndrome de intestino irritable - Diagnóstico y tratamiento - Mayo Clinic

   Accessed July 23, 2024. Kellerman RD, et al. Irritable bowel syndrome. In: Conn's Current Therapy 2024. Elsevier; 2024 https://www.clinicalkey.com. Accessed ...

10. Ensayos clínicos - Neurología

    ... syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.